July 21, 2009 / 4:31 AM / 10 years ago

Swiss stocks - Factors to watch on July 21

ZURICH, July 21 (Reuters) - The following are some of the main factors expected to affect Swiss stocks on Tuesday:

ACTELION ATLN.VX

Europe’s largest biotech company Actelion’s second quarter net profit rose 47 percent to 116 million Swiss francs ($108 million), helped by new patients and higher prices for key drug Tracleer and beat forecasts.

For related news click on [ATLN.VX]

NOVARTIS NOVN.VX

U.S. regulators have approved Novartis’ Tekturna HCT combination as an initial treatment for patients who are unlikely to respond sufficiently to a single drug, the Swiss company said on Tuesday.

For related news click on [NOVN.VX]

BANKS

Switzerland’s financial regulator FINMA is proposing measures to improve the capital base of cantonal and cooperative banks, it said on Monday.

For related news click on [BNK-CH]

ECONOMY [M-CH]

* Swiss June trade data is due at 0615 GMT.

* The Swiss National bank issues is due to issue its statistical report at 0700 GMT.

COMPANY STATEMENTS [CNR-CH]

* Holcim HOLN.VX - Disclosure of shareholdings [HOLN.VX]

* Zurich ZURN.VX announces amount of preferred securities tendered via its Offer to Purchase as of the Early Tender Date [ZURN.VX]

EQUITY RESEARCH [CH-RCH]

FOR COMPANIES TRADING EX-DIVIDEND, PLEASE CLICK ON:

.EX.S for all Swiss stocks

.EXSMI.S for blue chips

.EXNSMI.S for other stocks

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below